Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim of this work is to assess the impact of exposure to isoflurane or sevoflurane as an inhalation anesthetic on the oxidative stress and inflammatory conditions in patients undergoing elective moderate invasive surgery (laparoscopic cholecystectomy).
Oxidative stress is defined as "an imbalance between oxidants and antioxidants in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage.
Isoflurane, which has been utilized since the 1980s, has a particularly low metabolism rate and solubility, leading to reduced induction of anesthesia during surgery and shortened recovery time after surgery.
Sevoflurane began to be used a decade later and has a lower blood-gas partition coefficient than the other anesthetics, leading to rapid induction of anesthesia and fast awakening after anesthesia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group Iso | Experimental | Patients will receive general anesthesia and maintenance by isoflurane. |
|
| Group Sev | Experimental | Patients will receive general anesthesia and maintenance by sevoflurane. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isoflurane | Drug | Patients will receive general anesthesia and maintenance by isoflurane. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Serum level of superoxide dismutase | Serum level of superoxide dismutase (SOD) will be recorded. | 6 months postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Serum level of serum soluble programmed cell death-ligand 1 | Serum level of serum soluble programmed cell death-ligand 1 (sPD-L1) will be recorded. | 6 months postoperatively |
| Serum level of nuclear factor erythroid 2-related factor |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Eman A Ali, Master | Contact | 00201008005684 | eman.adel@med.asu.edu.eg |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ain Shams University | Recruiting | Cairo | 11591 | Egypt |
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
After the end of study for one year.
The data will be available upon a reasonable request from the corresponding author.
Not provided
Not provided
| ID | Term |
|---|---|
| D007530 | Isoflurane |
| D000077149 | Sevoflurane |
| ID | Term |
|---|---|
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D006845 | Hydrocarbons, Fluorinated |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sevoflurane |
| Drug |
Patients will receive general anesthesia and maintenance by sevoflurane. |
|
Serum level of nuclear factor erythroid 2-related factor (Nrf2) will be recorded.
| 6 months postoperatively |
| D006846 |
| Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |